Glyco-biomarkers/in vitro diagnostics (IVDs), developed from innovative technologies in glycoscience and glycomedice, will contribute to human health.


RCMG Inc. is founded by Dr. Narimatsu, a pioneer of establishing various technologies of glycoscience research over 30-years with great success, intellectual properties and know-how.

RCMG’s proprietary technology platform is able to continually create novel biomarkers/in vitro diagnostics (IVDs) to detect specific disease conditions suitable for the diversity of personalized medicine.

Current IVD pipeline includes inflammation, infectious disease, and oncology. Since glycosylation of cellular surfaces and secreted proteins reflects conditions of cells in patients, suffering from infections or cancers, glyco-biomarkers for specific diseases would create more accurate biomarkers.

RCMG’s pharmaco-glycoproteomics is able to stratify individual samples in view of drug response.

Pharmaco-glycoproteomics would contribute to obtain early signal efficacy of new drug in the development, stratify patient subpopulation and determine effective inclusion/exclusion criteria prior to large clinical trial for pharmaceutical companies.